• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Indivior PLC

    11/7/24 8:23:16 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email
    SC 13D/A 1 ef20038241_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549



    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    INDIVIOR PLC
    (Name of Issuer)

    Ordinary Shares, $0.50 nominal value per share
    (Title of Class of Securities)

    G4766E116
    (CUSIP Number)

    Richard Ting
    General Counsel & Managing Director
    Oaktree Capital Group Holdings GP, LLC
    333 South Grand Avenue, 28th Floor
    Los Angeles, California 90071

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 6, 2024
    (Date of Event Which Requires Filing of this Statement)



    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-l(e), 240.13d-l(f) or 240.13d-l(g), check the following box. ☒

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240 13d-7 for other parties to whom copies are to be sent.

    1       The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.


    *
    information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,see the Notes’).


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Value Opportunities Fund, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    5,545,556
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    5,545,556
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    5,545,556
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    4.4%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    1)
    Calculated based on 127,219,020 Ordinary Shares outstanding as of November 1, 2024, as disclosed in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (the “SEC”) on November 1, 2024.


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree London Liquid Value Opportunities Fund (VOF), L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    2,351,370
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    2,351,370
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    2,351,370
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    1.9%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    1)
    Calculated based on 127,219,020 Ordinary Shares, outstanding as of November 1, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on November 1, 2024.


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Phoenix Investment Fund, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    268,780
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    268,780
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    268,780
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.2%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    (1)
    Calculated based on 127,219,020 Ordinary Shares, outstanding as of November 1, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on November 1, 2024.


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Capital Management, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☒
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,356,274
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,356,274
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,356,274
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    1.1%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1)
    Calculated based on 127,219,020 Ordinary Shares, outstanding as of November 1, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on November 1, 2024.


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Fund GP I, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    8,165,706
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    8,165,706
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    8,165,706
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    6.4%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1)
    Calculated based on 127,219,020 Ordinary Shares, outstanding as of November 1, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on November 1, 2024.


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Capital Holdings, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    9,521,980
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    9,521,980
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,521,980
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.5%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)
    Calculated based on 127,219,020 Ordinary Shares, outstanding as of November 1, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on November 1, 2024.


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Capital Group Holdings GP, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    9,521,980
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    9,521,980
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,521,980
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.5%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)
    Calculated based on 127,219,020 Ordinary Shares, outstanding as of November 1, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on November 1, 2024.


    1
    NAMES OF REPORTING PERSONS
     
     
    Brookfield Asset Management ULC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Columbia, Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    9,521,980
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    9,521,980
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,521,980
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.5%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)
    Calculated based on 127,219,020 Ordinary Shares, outstanding as of November 1, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on November 1, 2024.


    This Amendment No. 1 (this “Amendment No. 1”) amends and supplements the Schedule 13D, originally filed on October 2, 2024 (the “Original Schedule 13D” and, together with this Amendment No. 1, the “Schedule 13D”). Except as set forth herein, the Original Schedule 13D remains in full force and effect.  Each capitalized term used but not defined herein has the meaning ascribed to such term in the Original Schedule 13D.

    Item 4.
    Purpose of Transaction

    Item 4 to the Schedule 13D is hereby amended to incorporate the following at the end thereof:

    On November 6, 2024, OC Management sent a letter to the board of directors of the Issuer (the “Board”) expressing concern with the Issuer’s underperformance over 1, 2 and 3-year periods, and the over 50% drop in the Issuer’s stock price over the past year. OC Management highlighted notable strategic and communications problems at the Issuer, including failures to address competition to the Issuer’s core product Sublocade and guidance reductions, which have exacerbated investor concerns around the Issuer’s strategy and the Board’s willingness and ability to hold management accountable. OC Management urged the Board to address these issues immediately and work with OC Management on refreshing the Board with directors who are committed to taking all steps necessary to improve shareholder value and hold management accountable as they seek to address the Issuer’s performance. OC Management expressed its interest in working constructively with the Board, but noted that it is evident that shareholders are extremely concerned about the Issuer’s performance and direction and would support action to effectuate change if necessary. A copy of the letter is attached hereto as Exhibit 1 and incorporated herein by reference.

    Item 5.
    Interest in Securities of the Issuer

    Item 5 (a) and (b) of the Original Schedule 13D are hereby amended and restated as follows:

    (a), (b)

    The information set forth in rows (7) through (11) of the cover pages of this Schedule 13D is incorporated by reference into this Item 5.

    The Reporting Persons hold an aggregate of 9,521,980 shares of Common Stock, representing 7.5% of the Common Stock outstanding as of the date hereof. All such ownership percentages of the securities reported herein are calculated assuming 127,219,020 Ordinary Shares outstanding as reported by the Issuer in its Form 6-K filed with the SEC on November 1, 2024.

    In this regard, OVO Fund is the direct holder of 5,545,556 Ordinary Shares. VOF Fund is the direct holder of 2,351,370 Ordinary Shares. OPI Fund is the direct holder of 268,780 Ordinary Shares. OC Management is the investment manager to Boston Patriot Arlington St LLC, an SMA account which directly holds 1,356,274 Ordinary Shares. Oaktree GP I is the indirect general partner of OVO Fund, VOF, and OPI Fund, and as such may be deemed to beneficially own an aggregate of 8,165,706 Ordinary Shares. OC Holdings is the indirect general partner of OVO Fund, VOF, OPI Fund, and Oaktree GP I, and as such may be deemed to beneficially own an aggregate of 9,521,980 Ordinary Shares. OC Group Holdings is the indirect owner of the Class B Units of OC Holdings, and as such may be deemed to beneficially own an aggregate of 9,521,980 Ordinary Shares. Such amounts include an aggregate of 146,560 Ordinary Shares, representing 0.1% of the then-outstanding Common Shares, which were acquired on the London Stock Exchange prior to filing of the Original Schedule 13D but were inadvertently omitted from such filing. Brookfield is the indirect owner of the Class A1 Units OC Holdings, and as such may be deemed to beneficially own an aggregate of 9,521,980 Ordinary Shares. Each of the Reporting Persons disclaims beneficial ownership of the reported securities and the filing of this Statement shall not be construed as an admission of such beneficial ownership for the purposes of Section 13(d) or 13(g) of the Exchange Act.

    Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission by any of the Reporting Persons that it is the beneficial owner of any of the Common Stock referred to herein for the purposes of Section 13(d) of the Act, or for any other purpose.


    Item 7.
    Material to be Filed as Exhibits

    Exhibit 24.1
    Joint Filing Agreement, dated as of October 3, 2024, by and among the Reporting Persons, incorporated by reference to Exhibit 24.1 to the Schedule 13D.

    Exhibit 1
    Letter, dated November 6, 2024, to the Board of Directors of the Issuer from Oaktree Capital Management, L.P.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 6, 2024
     
       

    OAKTREE VALUE OPPORTUNITIES FUND, L.P.
       
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE LONDON LIQUID VALUE OPPORTUNITIES FUND (VOF), L.P.
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE PHOENIX INVESTMENT FUND, L.P.
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE CAPITAL MANAGEMENT, L.P.
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE FUND GP I, L.P.
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE CAPITAL HOLDINGS, LLC
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory


     
    OAKTREE CAPITAL GROUP HOLDINGS GP, LLC
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    BROOKFIELD ASSET MANAGEMENT ULC
         
     
    By:
    /s/ Kathy Sarpash
     
    Name:
    Kathy Sarpash
     
    Title:
    Managing Director, Legal & Regulatory



    Get the next $INDV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Indivior with a new price target

      Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

      1/28/25 7:14:13 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Indivior with a new price target

      Piper Sandler initiated coverage of Indivior with a rating of Overweight and set a new price target of $22.00

      7/23/24 6:29:18 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Indivior with a new price target

      Craig Hallum initiated coverage of Indivior with a rating of Buy and set a new price target of $37.00

      4/3/24 7:45:35 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Indivior to Participate in Upcoming Investor Events

      RICHMOND, Va., May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New York City, NYJoe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 4th. Joe Ciaffoni will also participate in a fireside discussion on Wednesday, June 4th at 9:55 a.m. U.S. ET. Interested investors should contact their Jefferies representative to schedule a meeting. The fireside discussion will be publicly

      5/13/25 10:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

      SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder During Pregnancy" in the American Journal on Addictions, evaluating the use of SUBLOCADE for the treatment of opioid use disorder (OUD) during pregnancy and postpartum. Three sources of data evaluated in this retrospective study illustrated that the use of monthly SUBLOCADE during pregnancy demonstrated no increased risk and is consistent with the establi

      5/1/25 10:27:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Q1 2025 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com

      4/24/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Leadership Updates

    Live Leadership Updates

    See more
    • Indivior Announces Further Changes to Board of Directors

      RICHMOND, Va., March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director arrangements agreed with Oaktree Capital Management L.P. ("Oaktree"), the announcement on January 28, 2025 of the appointment of Dr. David Wheadon as Chair of the Company, the announcement on February 3, 2025 of the appointment of Daniel Ninivaggi as an Independent Non-Executive Director of the Company, and the announcement on February 27, 2025 of the appointment of Joe Ciaffoni as Chief Executive Officer of the Company, and following further discussions with Oaktree, the Company has agreed to m

      3/4/25 8:40:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    SEC Filings

    See more

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $INDV
    Financials

    Live finance-specific insights

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Indivior PLC

      SCHEDULE 13G/A - INDIVIOR PLC (0001625297) (Subject)

      5/13/25 8:50:25 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior PLC filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INDIVIOR PLC (0001625297) (Filer)

      5/8/25 12:21:52 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Indivior PLC

      SCHEDULE 13G/A - INDIVIOR PLC (0001625297) (Subject)

      5/6/25 3:52:41 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Indivior PLC

      SC 13G - INDIVIOR PLC (0001625297) (Subject)

      11/15/24 6:03:54 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Indivior PLC

      SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

      11/14/24 5:00:25 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Indivior PLC

      SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

      11/7/24 8:23:16 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Q1 2025 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com

      4/24/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces FY and Q4 2024 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.c

      2/20/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Q3 2024 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.

      10/24/24 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care